Health Technology Assessment (Sep 2004)

Rituximab (MabThera®) for aggressive non-Hodgkin's lymphoma: systematic review and economic evaluation

  • C Knight,
  • D Hind,
  • N Brewer,
  • V Abbott

DOI
https://doi.org/10.3310/hta8370
Journal volume & issue
Vol. 8, no. 37

Abstract

Read online

No abstracts available.